- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.07. | Jyong Biotech pursues global licensing partnerships for BPH drug | 3 | Investing.com | ||
| JYONG BIOTECH Aktie jetzt für 0€ handeln | |||||
| 23.07. | Jyong Biotech Ltd.: Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships | 304 | GlobeNewswire (Europe) | New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development... ► Artikel lesen | |
| 02.07. | Jyong Biotech presents drug candidate at BIO 2026 convention | 1 | Investing.com | ||
| 15.05. | Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 | 2 | GlobeNewswire (USA) | ||
| 15.05. | Jyong Biotech Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 28.04. | Jyong Biotech Ltd.: Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio | 4 | GlobeNewswire (USA) | ||
| 27.03. | Jyong Biotech Ltd.: Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 | 331 | GlobeNewswire (Europe) | New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development... ► Artikel lesen | |
| 12.02. | Jyong Biotech Ltd.: Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market ... | 336 | GlobeNewswire (Europe) | - Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value... ► Artikel lesen | |
| 30.01. | Jyong Biotech Ltd.: Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value | 335 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 19.12.25 | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | 579 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| 04.12.25 | Jyong Biotech Ltd.: Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry | 379 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 24.11.25 | Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs | 510 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 20.11.25 | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes | 434 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 11,300 | +15,19 % | Novavax-Aktie +20%: Woher kommt plötzlich die Fantasie? | Die Novavax-Aktie schoss zum Wochenauftakt um +20% in die Höhe und ging am Montagabend fast auf einem neuen 2-Jahreshoch aus dem Handel. Was steckt hinter dem Kurssprung des Impfstoffherstellers und... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,024 | +5,79 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| INFLARX | 1,468 | +7,23 % | BRANDMELDUNG bei InflaRx NV: Meine brandneue Prognose ändert einfach alles - Handeln Sie noch vor dem Wochenende! | ||
| INTELLIA THERAPEUTICS | 11,800 | +4,98 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| EDITAS MEDICINE | 2,590 | +2,37 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,363 | -3,71 % | NurExone Biologic: Alle Zeichen stehen auf Ausbruch und Rallye! | ||
| IBIO | 0,839 | +3,33 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,075 | +0,14 % | Geron-Aktie mit -98% - große Chance oder großes Risiko? | Die Geron-Aktie notiert aktuell bei 1,21 US$ und befindet sich erneut an einer langfristig wichtigen Unterstützungszone. Seit dem Zwischenhoch von 2024 hat der Biotech-Titel rund drei Viertel seines... ► Artikel lesen | |
| IMMUNITYBIO | 9,400 | +6,33 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 6,605 | +0,99 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,844 | +3,95 % | Myriad Genetics, Inc.: Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology | SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)... ► Artikel lesen | |
| MANNKIND | 2,925 | -3,97 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 11,610 | +14,84 % | What's Going on With Ginkgo Bioworks Stock on Friday? | ||
| IMMUNIC | 7,368 | +9,48 % | EQS-News: Immunic AG: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 13,020 | +9,60 % | Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call |
JYONG BIOTECH LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,090 Euro und damit -0,48 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JYONG BIOTECH LTD finden Sie auf Wallstreet Online.